RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · IEX Real-Time Price · USD
2.790
-0.090 (-3.12%)
At close: Jul 2, 2024, 4:00 PM
2.860
+0.070 (2.51%)
After-hours: Jul 2, 2024, 4:39 PM EDT
RAPT Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
126
Market Cap
97.38M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 1.53M | -2.29M | -59.95% |
| Dec 31, 2021 | 3.81M | -1.23M | -24.38% |
| Dec 31, 2020 | 5.04M | - | - |
| Dec 31, 2019 | 0 | - | - |
| Dec 31, 2018 | 0 | - | - |
| Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 140.46M |
| BrainsWay | 34.26M |
| Werewolf Therapeutics | 16.22M |
| Armata Pharmaceuticals | 4.70M |
| Sagimet Biosciences | 2.00M |
| BeyondSpring | 1.75M |
RAPT News
- 6 weeks ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month - Renovaro (NASDAQ:RENB) - Benzinga
- 7 weeks ago - RAPT Therapeutics Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients - GlobeNewsWire
- 3 months ago - VKTX, JANX and these biotech stocks are surging in 2024 - Invezz
- 4 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT - PRNewsWire
- 4 months ago - RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 4 months ago - RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 4 months ago - RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - Business Wire